Zobrazeno 1 - 10
of 25
pro vyhledávání: '"11"'
Autor:
Jennifer L. Taylor, Hussein Abdul-Hassan Tawbi, Lauren Miller, Jessica N. Filderman, Timothy J. Looney, Manoj Chelvanambi, John M. Kirkwood, Yan Lin, Deena M. Maurer, Melissa DeMark, Lilit Karapetyan, Ronald J Fecek, Walter J. Storkus, Anamika Bose, Lisa H. Butterfield, Geoffrey Lowman, Elizabeth Linch, Ahmad A. Tarhini, Devin B. Lowe, Fei Ding, Amy Rose, Pawel Kalinski
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for immunotherapy of cancer, vol 9, iss 11
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for immunotherapy of cancer, vol 9, iss 11
BackgroundA first-in-human, randomized pilot phase II clinical trial combining vaccines targeting overexpressed, non-mutated tumor blood vessel antigens (TBVA) and tyrosine kinase inhibitor dasatinib was conducted in human leukocyte antigen (HLA)-A2+
Autor:
Bernard A. Fox, Sachin Puri, Walter J. Urba, Christopher Dubay, Bharat H. Joshi, Brendan D. Curti, Christopher Paustian, Keith S. Bahjat, Jing Han, Janet C. Siebert, Daniel Healy
Publikováno v:
Journal for Immunotherapy of Cancer
The Phase I/II clinical trial randomized patients to GVAX immunotherapy (two prostate cancer cell lines that secrete GM-CSF, Cell Genesys Inc.) alone or in combination with non-myeloablative chemotherapy and adoptive transfer of PBMC. Pre and week 11
Autor:
Thomas P. Davis, Kevin Mancini, Jessica Price, Richard Hernandez, Craig Carey, Arthur DeCillis
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundGEN-011 is a personalized neoantigen-targeted peripheral blood T cell therapy (NPT) developed for the treatment of adult patients (pts) with solid tumors. The proprietary ATLAS™ (Antigen Lead Acquisition System) will be used to identify t
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
ObjectiveMucosal-associated invariant T (MAIT) cells are innate T cells with immunoregulatory activity and were recently found to be associated with various tumor types. The role of intrasinusoidal MAIT cells in hepatocellular carcinoma (HCC) has not
Autor:
Donald P. Lawrence, Kathleen L. Pfaff, Kristen Felt, Elizabeth I. Buchbinder, Anita Giobbie-Hurder, Patrick A. Ott, David F. McDermott, Evisa Gjini, Mariano Severgnini, Jacquelyn O. Wolff, Matthew Nazzaro, Ryan J. Sullivan, Rizwan Haq, Scott J. Rodig, F. Stephen Hodi
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 11 (2021)
BackgroundAngiogenic factors promote the growth of tumor vasculature, modulate lymphocyte trafficking into tumors, and inhibit maturation of dendritic cells. We hypothesized that MEDI3617, a human IgG1 kappa monoclonal antibody directed against human
Autor:
Niranjan Y. Sardesai, Alfredo Perales-Puchalt, Tanner M. Johanns, Sarah Rochestie, Neil Cooch, Joann Peters, Gavin P. Dunn
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundTumor neoantigens are epitopes derived from tumor-specific mutations. Such mutations can be incorporated in personalized vaccines to prime T cell responses against tumor specific antigens. DNA vaccines delivered with electroporation have re
Autor:
Haydn T. Kissick, Maria Cardenas, Jennifer W Carlisle, Adeboye O. Osunkoya, Caroline S. Jansen, Viraj A. Master, Patrick Mullane, Mehmet Asim Bilen, Rachel Greenwald, Ewelina Sobierajska, Nataliya Prokhnevska
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundTumor infiltrating T-cells have a prognostic benefit in many tumor types,1–8 and we recently sought to determine whether the level of T-cell infiltration into renal tumors predicts clinical outcomes. In our recent publication,9 we showed
Autor:
Michael A. Curran, Arthur Liu
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundThe majority of patients with pancreatic ductal adenocarcinoma (PDAC) fail to derive any durable responses from single agent immune checkpoint blockade therapy. This refractory state originates from PDAC's unique tumor microenvironment that
Autor:
Sonali Jindal, Hong Chen, Christopher J. Logothetis, Ana Aparicio, Rebecca S. S. Tidwell, Paul G. Corn, Padmanee Sharma, Bilal A. Siddiqui, Ashwin Varma, James P. Allison, Sumit K. Subudhi, Shalini S. Yadav, Sreyashi Basu
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
BackgroundImmune checkpoint therapy (ICT) has low response rates in patients with metastatic castration-resistant prostate cancer (mCRPC), in part due to few T cells in the tumor microenvironment (TME). Anti-cytotoxic T lymphocyte-associated protein
Autor:
Richa Gupta, Joseph N. Contessa, Adebowale J. Adeniran, Hailey Wyatt, Kurt A. Schalper, Benjamin Y. Lu, Nicole Gianino, Adam Aguirre-Ducler, Sarah B. Goldberg, Lucia B. Jilaveanu, Veronica Chiang, Matthew Ribeiro, Harriet M. Kluger
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 10 (2021)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Despite unique genetic alterations within brain metastases (BrMs) and an immunologically distinct surrounding microenvironment, the composition and functional properties of tumor-infiltrating lymphocytes within BrM remain largely unexplored. In parti